about
sameAs
Consensus statement of the Spanish Society of Rheumatology on risk management of biologic therapy in rheumatic patientsTumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literaturePrevalence and clinical significance of anti-cyclic citrullinated peptide and antikeratin antibodies in palindromic rheumatism. An abortive form of rheumatoid arthritis?Variation at FCGR2A and functionally related genes is associated with the response to anti-TNF therapy in rheumatoid arthritisImmature blood vessels in rheumatoid synovium are selectively depleted in response to anti-TNF therapy.CNstream: a method for the identification and genotyping of copy number polymorphisms using Illumina microarrays.Clinicopathological correlations of podoplanin (gp38) expression in rheumatoid synovium and its potential contribution to fibroblast platelet crosstalk.Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysisDiffering specificities and isotypes of anti-citrullinated peptide/protein antibodies in palindromic rheumatism and rheumatoid arthritisCardiovascular disease in immune-mediated inflammatory diseases: A cross-sectional analysis of 6 cohortsLack of replication of interactions between polymorphisms in rheumatoid arthritis susceptibility: case-control study.Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only studyDifferential Th1/Th2 cytokine patterns in chronic arthritis: interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathiesMultidisciplinary dermatology-rheumatology management for patients with moderate-to-severe psoriasis and psoriatic arthritis: a systematic review.Ectopic lymphoid neogenesis is strongly associated with activation of the IL-23 pathway in rheumatoid synovitisPalindromic rheumatism and other relapsing arthritis.Urine metabolome profiling of immune-mediated inflammatory diseases.The effect of smoking on clinical and structural damage in patients with axial spondyloarthritis: A systematic literature review.Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical featuresEffectiveness of conventional disease-modifying antirheumatic drugs in psoriatic arthritis: A systematic review.Notch-regulated miR-223 targets the aryl hydrocarbon receptor pathway and increases cytokine production in macrophages from rheumatoid arthritis patientsCD271(+) stromal cells expand in arthritic synovium and exhibit a proinflammatory phenotypeImmunopathologic characterization of ultrasound-defined synovitis in rheumatoid arthritis patients in clinical remission.Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.Analysis of TNFAIP3, a feedback inhibitor of nuclear factor-kappaB and the neighbor intergenic 6q23 region in rheumatoid arthritis susceptibility.Diagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritis.Patients with rheumatoid arthritis in clinical remission and ultrasound-defined active synovitis exhibit higher disease activity and increased serum levels of angiogenic biomarkers.Morphea associated with the use of adalimumab: a case report and review of the literature.Immunopathology of rheumatoid arthritis.European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.Safety profile of biological therapies for treating rheumatoid arthritis.The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis.Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review.Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review.Benefit of health education by a training nurse in patients with axial and/or peripheral psoriatic arthritis: A systematic literature review.The Transcriptional Coactivator Bob1 Is Associated With Pathologic B Cell Responses in Autoimmune Tissue Inflammation.Synovial tissue research: a state-of-the-art review.Synovial vascular patterns and angiogenic factors expression in synovial tissue and serum of patients with rheumatoid arthritis.Distinct synovial immunopathology in Behçet disease and psoriatic arthritis.Patient global assessment in psoriatic arthritis - what does it mean? An analysis of 223 patients from the Psoriatic arthritis impact of disease (PsAID) study.
P50
Q26829810-D7C71A1C-0294-4D11-ABD4-5A69F896E1BCQ27012134-6C7CF660-2724-459A-A952-B6155C1D586EQ28202437-8C49AD4A-7631-439C-BC7F-F0E29B785D02Q28545783-8E51281C-CB14-4C17-99C1-60DE8DD617D2Q30941105-61F73379-A811-4ABA-99B9-D051039D657AQ33581300-FC061772-F679-4020-9AAC-B45B5DAA0A8DQ33763542-169C4333-B6D6-438D-B004-77718DD2E4B9Q33766353-96DA36FA-167D-4AD5-BB59-CFC734116488Q33805043-0CBB5C14-5036-4116-B9A5-4D59A21EE9D1Q33879759-18C517B7-B48D-457F-9E3A-7724ED80AAFBQ34393009-732A380B-05FA-4337-BBEB-0F14B019E45AQ35544546-50C07AE6-0FF7-467A-9BEF-4288409E362FQ35549213-F7DAB19C-6D52-4251-9AA7-A40344960FC3Q35800115-73D3E78E-D652-4CDB-B85F-D44D19A460BFQ35834582-5412C196-A21C-4E89-A194-51837ED4F8ACQ35904079-C8E4C532-7332-412E-9B50-39AEDA4E1AD9Q36127459-8318B89D-1B8E-4DB1-A707-56A90EF5EE95Q36225767-2AFAC23E-EDB9-4990-AD12-16F03A012648Q36245883-CEF6E1DD-2C2F-4567-A9AA-698E77EEB590Q36250112-D2AFB581-C856-4F85-BBC5-1448AFDC9A5CQ36536348-588283A6-2233-402A-886E-6EAD060C20EEQ36687372-0F0D1403-296F-45CF-AA22-45451A36326CQ36758489-BFDCF98E-252D-4EE3-84AB-735276B4729AQ37080199-4FF5454F-1B04-4111-B68F-6E7F899C9A34Q37206928-EBD4B90F-92E7-4008-9CC9-58224C0E8AF3Q37453967-CB078F28-1D90-40E7-9939-733DA920FAAFQ37689654-9E94484E-3D6E-4F0B-9643-C43A62C4DA80Q37957758-2C041619-0BFC-45E3-850E-75A94B46802EQ38097955-F021D6C4-4583-4A0E-A71F-B46D5546B1FBQ38661777-CA8FAD4C-2C4B-41A8-8AA8-9685ECE3CA29Q38665700-FECD7B9C-CFB9-4258-A27E-B0A43821E378Q38755133-3A0B6C35-C2B9-4E56-BC67-BDF2D86FAAFFQ38783099-A952C004-DE88-47C4-A398-BEEABF33C274Q38857820-B14AB49E-392F-49A1-8F07-B71F69F7444CQ38932791-0F48E13A-0AB0-4BAD-83DD-80F0F5A20FD4Q39139092-1AD8980F-1019-479B-97AB-B7118D79DAC4Q39431367-459E5C47-505F-43D4-A161-2FB41FBF3537Q39746346-1C7CDA6B-60D3-4C1D-80E0-373AF8809C1FQ39746346-CA3EB2E7-B420-4C17-BA93-BAA25CB8F2F9Q39872694-2044EDD4-708B-4C13-AE11-4139815156FA
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Juan D Cañete
@ast
Juan D Cañete
@en
Juan D Cañete
@es
Juan D Cañete
@sl
type
label
Juan D Cañete
@ast
Juan D Cañete
@en
Juan D Cañete
@es
Juan D Cañete
@sl
altLabel
Raimon Sanmartí
@en
prefLabel
Juan D Cañete
@ast
Juan D Cañete
@en
Juan D Cañete
@es
Juan D Cañete
@sl
P1053
M-4428-2017
M-4434-2017
P106
P21
P2798
P31
P3829
P3835
juan-d-canete-
P496
0000-0003-2606-0573